Become a member
Log In
Contact
Donate
The full conference programme for the conference on One-Carbon Metabolism and Homocysteine has now been confirmed and the Chairman of the society, Martyn Hooper MBE, who has been invited to give the patient’s perspective on how the problems with the diagnosing and treating Pernicious Anaemia is impacting on the everyday lives of patients. Martyn is now busy working on his 25-minute presentation. The conference takes place over four days at the University of Aarhus in Denmark next month.
It’s going to be a very interesting gathering that will address and lead to discussions on many of the issues that we, as patients, face.
Presentations will include:
Presentations will include:
‘Black holes in the universe of vitamin B12’
‘Homocysteine determination today – is it still relevant?’
‘Surprises from the study of patients with inherited disorders of cobalamin metabolism’
‘Combined indicator of B12 deficiency (cB12). Optimized sequential application of individual biomarkers and their combinations’
‘B vitamin status in non-pregnant, pregnant and lactating mothers and their infants’
‘Utility of new-born screening markers to diagnose new-borns at risk of vitamin B-12 deficiency second to maternal vitamin B-12 deficiency’
‘New perspectives on vitamin B-12 deficiency in low income populations: assessment and prevalence’.
‘Behavioural alterations associated with vitamin B12 deficiency in the TCblR/CD320 KO mouse’.
There’s even a presentation on the old classic debate about whether Cyanocobalamin or Hydroxocobalamin is best to treat Pernicious Anaemia – ‘Cyano-B12 versus hydroxo-B12: New insights on transport and accumulation’.
‘Homocysteine determination today – is it still relevant?’
‘Surprises from the study of patients with inherited disorders of cobalamin metabolism’
‘Combined indicator of B12 deficiency (cB12). Optimized sequential application of individual biomarkers and their combinations’
‘B vitamin status in non-pregnant, pregnant and lactating mothers and their infants’
‘Utility of new-born screening markers to diagnose new-borns at risk of vitamin B-12 deficiency second to maternal vitamin B-12 deficiency’
‘New perspectives on vitamin B-12 deficiency in low income populations: assessment and prevalence’.
‘Behavioural alterations associated with vitamin B12 deficiency in the TCblR/CD320 KO mouse’.
There’s even a presentation on the old classic debate about whether Cyanocobalamin or Hydroxocobalamin is best to treat Pernicious Anaemia – ‘Cyano-B12 versus hydroxo-B12: New insights on transport and accumulation’.
The above is just a small selection of the 68 papers that will be presented over the four days.
It’s heartening to know that so much research is taking place into the problems with the diagnosis and treatment of Pernicious Anaemia in particular and B12 Deficiency in general and we are grateful for the opportunity to be given the opportunity to give the patients’ perspective on these problems and to make the researchers not only aware of how late diagnosis and insufficient treatment is impacting on the lives of patients but also to make them aware of how we, as a society, can help them in their research programmes.
After an absence of several years, whil I attended to the symptoms of an acute Porphyria, I have returned to find great advances in the society, for which you are to ve commended. This is one of the best run support groups ever encountered..